Table 3. Blinatumomab in... | American Society of Hematology

Table 3.

Blinatumomab in frontline/MRD-positive trials for AYA with Ph-negative ALL

Group	Phase	Condition	Age	Disease	End point	N	CT
HOVON	2	BLIN prior to induction	18-70 y	Ph−	MRD	71	NCT03541083
CZECRIN (Blina-CELL)	2	BLIN prior to induction	18-65 y	Ph−	MRD	45	NCT04554485
MDACC	2	INO + BLINA + chemotherapy	14 y+	Ph−	RFS	80	NCT02877303
GIMEMA (LAL2317)	2	BLIN post induction	18-65 y	Ph−	MRD	149	NCT03367299
PETHEMA (BLIN-01)	2	BLIN post induction in HR ALL	18-55 y	Ph−	MRD	11	NCT03523429
GMALL (MOLACT-1)	2	BLIN post induction in MRD+ ALL	18 y+	Ph−	MRD	84	NCT03109093
GRAALL (B/2014-QUEST)	2	BLIN frontline in HR ALL	18-59 y	Ph−	DFS	95	NCT03709719
Israeli Medical Association	2	BLIN prior to allo-HSCT in HR ALL	18-29y	Ph−	EFS	110	NCT04334993
MDACC	2	BLIN in MRD+ ALL	18 y+	Ph+/−	RFS	40	NCT02458014
ECOG-ACRIN	3	BLIN post induction	30-70 y	Ph−	OS	488	NCT02003222
University of Wisconsin	2	BLIN in MRD+ or HR ALL before allo-HSCT	< = 25 y	Ph−	MRD	35	NCT04556084
MDACC	2	BLIN post allo-HSCT in MRD+ (4 cycles)	1-70 y	Ph+/−	PFS	23	NCT02807883
University of Wisconsin	2	BLIN after T/B-cell depleted allo-HSCT	< = 25 y	Ph+/−	Feasibility	25	NCT04746209
Johns Hopkins	1/2	BLIN post allo-HSCT (B-ALL and NHL)	18 y+	Ph+/−	OS	64	NCT03114865
University of Munich	2	BLIN + DLI post allo-HSCT in MRD+	18 y+	Ph+/−	Safety	12	NCT03982992

Group	Phase	Condition	Age	Disease	End point	N	CT
HOVON	2	BLIN prior to induction	18-70 y	Ph−	MRD	71	NCT03541083
CZECRIN (Blina-CELL)	2	BLIN prior to induction	18-65 y	Ph−	MRD	45	NCT04554485
MDACC	2	INO + BLINA + chemotherapy	14 y+	Ph−	RFS	80	NCT02877303
GIMEMA (LAL2317)	2	BLIN post induction	18-65 y	Ph−	MRD	149	NCT03367299
PETHEMA (BLIN-01)	2	BLIN post induction in HR ALL	18-55 y	Ph−	MRD	11	NCT03523429
GMALL (MOLACT-1)	2	BLIN post induction in MRD+ ALL	18 y+	Ph−	MRD	84	NCT03109093
GRAALL (B/2014-QUEST)	2	BLIN frontline in HR ALL	18-59 y	Ph−	DFS	95	NCT03709719
Israeli Medical Association	2	BLIN prior to allo-HSCT in HR ALL	18-29y	Ph−	EFS	110	NCT04334993
MDACC	2	BLIN in MRD+ ALL	18 y+	Ph+/−	RFS	40	NCT02458014
ECOG-ACRIN	3	BLIN post induction	30-70 y	Ph−	OS	488	NCT02003222
University of Wisconsin	2	BLIN in MRD+ or HR ALL before allo-HSCT	< = 25 y	Ph−	MRD	35	NCT04556084
MDACC	2	BLIN post allo-HSCT in MRD+ (4 cycles)	1-70 y	Ph+/−	PFS	23	NCT02807883
University of Wisconsin	2	BLIN after T/B-cell depleted allo-HSCT	< = 25 y	Ph+/−	Feasibility	25	NCT04746209
Johns Hopkins	1/2	BLIN post allo-HSCT (B-ALL and NHL)	18 y+	Ph+/−	OS	64	NCT03114865
University of Munich	2	BLIN + DLI post allo-HSCT in MRD+	18 y+	Ph+/−	Safety	12	NCT03982992

BLIN: blinatumomab; DFS, disease-free survival; DLI: donor lymphocyte infusion; HR, high risk; RFS, relapse-free survival.